Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H43NO8.ClH |
Molecular Weight | 546.093 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12[C@H](OC(=O)CCN(C)C)[C@H](OC(C)=O)[C@@]3(C)O[C@](C)(CC(=O)[C@]3(O)[C@@]1(C)[C@@H](O)CCC2(C)C)C=C
InChI
InChIKey=VIRRLEDAYYYTOD-YHEOSNBFSA-N
InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1
DescriptionSources: http://adisinsight.springer.com/drugs/800001302Curator's Comment: Description was created based on several sources, including
http://www.genome.jp/dbget-bin/www_bget?D01697 and https://www.ncbi.nlm.nih.gov/pubmed/12499623
Sources: http://adisinsight.springer.com/drugs/800001302
Curator's Comment: Description was created based on several sources, including
http://www.genome.jp/dbget-bin/www_bget?D01697 and https://www.ncbi.nlm.nih.gov/pubmed/12499623
Colforsin daropate (a derivative of Colforsin) is cardiotonic, adenylate cyclase activator. It is reported as an ingredient of Adehl in Japan. Colforsin daropate hydrochloride is used for the treatment of acute heart failure. Colforsin daropate is capable of directly stimulating adenylate cyclase, which in turn causes vasorelaxation via elevated intracellular concentrations of cyclic adenosine monophosphate, making it a useful therapeutic tool in treating cerebral vasospasm.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10217303
Curator's Comment: COLFORSIN DAROPATE has been reported to penetrate the blood- brain barrier after peripheral administration and can thereby be used to activate adenylyl cyclase in the CNS
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2097167 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10511949 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Adehl Approved UseAcute heart failure |
PubMed
Title | Date | PubMed |
---|---|---|
Antiinflammatory effects of colforsin daropate hydrochloride, a novel water-soluble forskolin derivative. | 2001 Jun |
|
Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. | 2001 Jun |
|
Impaired intracellular signal transduction via cyclic AMP contributes to cerebral vasospasm in rats with subarachnoid hemorrhage. | 2002 Apr |
|
Influence of colforsin daropate hydrochloride on internal mammary artery grafts. | 2002 Apr |
|
Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers. | 2002 Apr 15 |
|
Effect of mild hypothermia on inodilator-induced vasodilation of pial arterioles in cats. | 2002 Oct |
|
Expression of aquaporin 8 and its up-regulation by cyclic adenosine monophosphate in human WISH cells. | 2003 Apr |
|
Effect of prophylactic bronchodilator treatment with intravenous colforsin daropate, a water-soluble forskolin derivative, on airway resistance after tracheal intubation. | 2003 Jul |
|
Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. | 2004 Aug |
|
Functional changes in adenylyl cyclases and associated decreases in relaxation responses in mesenteric arteries from diabetic rats. | 2005 Nov |
|
Beta-adrenoceptor-mediated vasodilation of retinal blood vessels is reduced in streptozotocin-induced diabetic rats. | 2008 Aug-Sep |
|
Colforsin-induced vasodilation in chronic hypoxic pulmonary hypertension in rats. | 2010 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12826837
0.75 ug kg-1 x min-1 colforsin daropate intravenously
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14512698
COLFORSIN DAROPATE (10(-7)-10(-5) mol/l) inhibited [(3)H]thymidine incorporation into cultured rat MCs in a concentration-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB33262
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
100000126205
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
31429
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
138605-00-2
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
DTXSID90930165
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
444028
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY | |||
|
C6P4R272GT
Created by
admin on Fri Dec 15 18:07:39 GMT 2023 , Edited by admin on Fri Dec 15 18:07:39 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD